Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Exploratory Study of Mavrilimumab Versus Anti-tumor Necrosis Factor in Subjects With Rheumatoid Arthritis

NCT01715896 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT01715896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01715896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Exploratory Study of Mavrilimumab Versus Anti-tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2013
Completion date
February 28, 2015
Enrollment
215 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis